Innova Captab Ltd

NSE: INNOVACAP | BSE: 544067

₹949.55

up-down-arrow16.60 (1.78%)

As on 19-Jun-2026IST

Market cap

info icon

₹5,446 Cr

Revenue (TTM)

info icon

₹1,630 Cr

P/E Ratio

info icon

38.6

P/B Ratio

info icon

5

Div. Yield

info icon

0.2 %

Value Research Rating

Quality Score fund-quick-summary-circle

Quality Score6/10

Growth Score fund-quick-summary-circle

Growth Score8/10

Valuation Score fund-quick-summary-circle

Valuation Score4/10

Momentum Score fund-quick-summary-circle

Momentum Score9/10

Innova Captab Share Price

Compare

High:loading Low:loading Return: loading

High:loading Low:loading Return: loading

Max:loading Min:loading Median:loading

Max:loading Min:loading Median:loading

loading...
loading...
loading...
loading...
loading...
loading...
loading...
loading...

Stock Range

Today’s Range

Low: 932.10 High: 956.85

52 Week Range

Low: 622.00 High: 978.00

Liquidityliquidity High

Low Moderate High

Fundamentals

  • Net Profit (TTM)Net Profit (TTM) information

    ₹141 Cr

  • ROEROE information

    13.7 %

  • ROCEROCE information

    15 %

  • Industry P/EIndustry P/E information

    44.27

  • EV/EBITDAEV/EBITDA information

    23.1

  • Debt to EquityDebt to Equity information

    0.3

  • Book ValueBook Value information

    ₹190.6

  • EPSEPS information

    ₹24.6

  • Face valueFace value information

    10

  • Shares outstandingShares outstanding information

    57,224,929

8 Years Aggregate

CFO

₹525.08 Cr

EBITDA

₹928.11 Cr

Net Profit

₹577.69 Cr

Performance

Company
YTD
1 Month
3 Months
1 Year
3 Years
5 Years
10 Years
Innova Captab
31.9 8.3 34.7 11.2 -- -- --
BSE Healthcare
10.2 1.2 12.0 10.9 24.0 14.1 12.4
As on 19-Jun-2026
Company
2025
2024
Innova Captab
-35.1 110.3
BSE Small Cap
-6.6 29.0
BSE Healthcare
-3.3 43.1

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

View Details
loading...

*All values are in (₹ Cr)

loading...

*All values are in (₹ Cr)

loading...

*All values are in (₹ Cr)

Key Ratios

View Details
loading...

loading...

loading...

5Y Avg -- 3Y Avg -- TTM --

loading...

P/E Ratio

--

--Min --Median --Max

loading...

P/B Ratio

--

--Min --Median --Max

loading...

Earnings Yield (%)

--

Earnings Yield (%) = EBIT / Enterprise value

PEG Ratio

--

Price = Price / Earnings to growth ratio

loading...

loading...

loading...

Peers

View Details
Company
Price (₹) Market Cap (₹ Cr) Revenue (TTM) Net Profit (TTM) OPM (%) ROE (%) P/E P/B
Innova Captab
949.6 5,446.1 1,630.0 140.9 11.9 13.7 38.6 5.0
3,246.2 26,558.6 1,339.4 356.4 33.2 23.2 74.5 16.1
405.9 15,522.7 2,268.6 150.1 10.6 5.4 86.6 4.0
786.9 19,473.1 5,365.6 595.0 16.6 13.3 32.7 3.8
889.0 15,918.4 4,078.3 1,371.9 30.2 15.9 11.2 1.7
1,608.6 18,428.2 1,421.6 -73.8 1.8 -1.1 -- 3.2
158.9 21,141.8 8,869.1 -383.1 1.0 -4.2 -- 2.6
1,361.8 22,492.1 1,284.3 134.4 -- 30.7 91.2 17.5
440.8 17,797.8 3,738.7 316.7 12.5 7.5 56.2 3.7
2,011.1 32,676.4 3,373.0 199.0 12.6 5.9 153.4 6.6

Shareholding Pattern

View Details
loading...
These are advertorial stories which keeps Value Research free for all. Click here to mark your interest for an ad-free experience in a paid plan

News & Analysis

All News

IPO: Innova Captab

5 min readBy  Vishal Goyal

About Innova Captab

Innova Captab Limited, an integrated pharmaceutical company, engages in the research and development, manufacture, distribution, and marketing of drugs in India and internationally. The company provides contract development and manufacturing...  organization services to Indian pharmaceutical companies. It is also offers various generic formulation products, including cephalosporins, proton pump inhibitor, anticholinergic and heparin NSAIDs, analgesics and antipyretic, anticold and antiallergic, antiemetic, antidiabetic, antispasmodic, antifibrinolytic, cardiovascular, antioxidant and vitamins, antihyperuricemia and antigout, fluoroquinolone and macrolide, nootropics and neurotonics/neurotrophics, antiulcerative, antimalarial anxiolytic, anticonvulsant and antipsychotic, bladder and prostate disorder, antifungal, anthelmintic and antiviral, anticholinergic, anti-asthmatic, and bronchodilator products in the form of tablets, capsules, dry syrups, dry powder injection, ointments, and liquid orals. The company sells its branded generic products through a network of distributors and pharmacies, as well as online channels in various e-commerce pharmacy sites. Innova Captab Limited was incorporated in 2005 and is based in Panchkula, India. 

  • Incorporated

    2005

  • Chairman

    Manoj Kumar Lohariwala

  • Managing Director

    Vinay Lohariwala

  • Headquarters

    Navi Mumbai, Maharashtra

  • Website

    www.innovacaptab.com

Edit peer-selector-edit

FAQs for Innova Captab

The share price of Innova Captab Ltd is ₹949.55 (NSE) and ₹951.70 (BSE) as of 19-Jun-2026 IST. Innova Captab Ltd has given a return of 11.21% in the last 1 years.

The P/E ratio of Innova Captab Ltd is 38.65 times as on 19-Jun-2026, a 13 discount to its peers’ median range of 44.27 times.
The P/B ratio of Innova Captab Ltd is 4.99 times as on 19-Jun-2026, a 19 premium to its peers’ median range of 4.19 times.


PE & PB ratio at the end of financial year.


Year P/E Ratio P/B Ratio
2026
27.91
3.61
2025
39.15
5.23
2024
27.18
3.09
2023
0.00
0.00
2022
0.00
0.00

The 52-week high and low of Innova Captab Ltd are Rs 978.00 and Rs 622.00 as of 20-Jun-2026.

Innova Captab Ltd has a market capitalisation of ₹ 5,446 Cr as on 19-Jun-2026. As per SEBI classification, it is a Small Cap company.

Before investing in Innova Captab Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.

For guidance, explore our expert-curated portfolios and Stock recommendations with Value Research Stock Advisor.
Want to explore on your own? Click here to see how this stock scores on quality, growth, valuation, and momentum.